REDEFINING ADC PRECISION: NATURE’S BLUEPRINT, OUR BREAKTHROUGH

Scientific Platforms

Manhattan BioSolutions engineers next-generation antibody-drug conjugates (ADCs) inspired by evolutionary mechanisms, delivering unparalleled tumor targeting and payload release to conquer advanced cancers. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms

>>>
In the News
Contact Us
For business development or general inquiries, please fill out a contact form. If you’re an accredited investor, please contact us at ir @ manhattanbiosolutions.com

Office
Center Avenue, Fort Lee
New Jersey, NY 07024

Laboratory
80 5th Avenue, 1002
New York, NY 10011